| Literature DB >> 35056543 |
Fei Yu1,2,3, Min Zhang2,3, Junfeng Sun2,3, Fang Wang2,3, Xiangfei Li1, Yan Liu2,3, Zhou Wang2,3, Xinrui Zhao1,4, Jianghua Li1,4, Jian Chen1,4, Guocheng Du1,4,5, Zhenglian Xue2,3.
Abstract
To improve the screening efficiency of high-yield neomycin sulfate (NM) Streptomyces fradiae strains after mutagenesis, a high-throughput screening method using streptomycin resistance prescreening (8 μg/mL) and a 24-deep well plates/microplate reader (trypan blue spectrophotometry) rescreening strategy was developed. Using this approach, we identified a high-producing NM mutant strain, Sf6-2, via six rounds of atmospheric and room temperature plasma (ARTP) mutagenesis and screening. The mutant displayed a NM potency of 7780 ± 110 U/mL and remarkably stable genetic properties over six generations. Furthermore, the key components (soluble starch, peptone, and (NH4)2SO4) affecting NM potency in fermentation medium were selected using Plackett-Burman and optimized by Box-Behnken designs. Finally, the NM potency of Sf6-2 was increased to 10,849 ± 141 U/mL at the optimal concentration of each factor (73.98 g/L, 9.23 g/L, and 5.99 g/L, respectively), and it exhibited about a 40% and 100% enhancement when compared with before optimization conditions and the wild-type strain, respectively. In this study, we provide a new S. fradiae NM production strategy and generate valuable insights for the breeding and screening of other microorganisms.Entities:
Keywords: Streptomyces fradiae; atmospheric and room temperature plasma (ARTP) mutagenesis; fermentation medium optimization; high-throughput screening; neomycin sulfate (NM)
Year: 2022 PMID: 35056543 PMCID: PMC8780280 DOI: 10.3390/microorganisms10010094
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1ARTP mutagenesis and screening schematic. RF: radio-frequency.
Figure 2Pictures of the ARTP mutation breeding system. (A) The front view; (B) The operation chamber; (C) The operation interface.
Figure 3Prescreening mutant strains on resistant plates containing different streptomycin concentrations (0, 2, 4, 6, 8, and 10 μg/mL).
The distribution fraction of mutant strains on streptomycin resistance plates.
| The Concentrations of Streptomycin (μg/mL) | Distribution Fraction of Mutant Strains with Different NM Potency (%) | |||
|---|---|---|---|---|
| <6000 * | 6000–6500 * | 6500–7000 * | >7000 * | |
| 2 | 49.6 | 42.3 | 8.1 | 0 |
| 4 | 32.6 | 44.4 | 20.5 | 2.5 |
| 6 | 22.6 | 30.5 | 38.6 | 8.3 |
| 8 | 12.1 | 22.4 | 48.7 | 16.8 |
The 80, 60, 30, and 20 mutant strains were randomly selected from 2, 4, 6, and 8 μg/mL streptomycin plates, respectively, and underwent 24-deep well plates fermentation and further NM potency assessment. * Represents NM potency (U/mL).
Figure 4Optimization of the rescreening method for high-producing NM mutant strains. (A) Fermentation correlations between 24-deep well plates and 250 mL shake flasks; (B) Fermentation correlations between 48-deep well plates and 250 mL shake flasks; (C) A full-wavelength scan of TB and NM reaction solutions; (D) The influence of different TB volumes (1.0 × 10−4 mol/L) on the absorbance at different NM standard potencies; (E) A NM standard curve; (F) Correlations between TB spectrophotometry using a microplate reader and HPLC for NM potency determination.
Spike and recovery experiments.
| Addition Amount (μg) | Measured Amount (μg) | Recovery Rate (%) | Average Recovery Rate (%) | |
|---|---|---|---|---|
| 3 | 2.8943 ± 0.0289 | 96.4770 | 98.4684 | 3.2700 |
| 5 | 4.7008 ± 0.0564 | 94.0163 | ||
| 7 | 6.6878 ± 0.0535 | 95.5401 | ||
| 9 | 9.0537 ± 0.1358 | 100.5962 | ||
| 11 | 11.1122 ± 0.2224 | 101.0200 | ||
| 13 | 13.3626 ± 0.2138 | 102.7892 | ||
| 15 | 14.8260 ± 0.3707 | 98.8401 |
The experiments were performed in triplicate. RSD: relative standard deviation.
Figure 5Iterative ARTP mutagenesis and investigations of genetic stability. (A) A S. fradiae lethality plot by ARTP mutagenesis; (B) The distribution of mutant strains with different NM potencies in each ARTP round; (C) The cumulative effects of iterative ARTP mutagenesis on NM potency in mutant strains; (D) Genetic stability of the high-producing NM mutant strain, Sf6-2. WT: wild-type strain (S. fradiae GC 6010); R: positive mutation rate; R: mutation rate; R: R and R.
Plackett-Burman design matrix with corresponding results. X1–X10: independent variables; D1–D4: dummy variables; (+): high level; (−): low level.
| Trial No. | Variables | NM Potency | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| 1 | + | − | + | − | + | + | + | + | − | − | + | + | − | + | 8912 ± 107 |
| 2 | + | + | − | + | + | − | − | − | − | + | − | + | − | + | 8284 ± 116 |
| 3 | + | − | + | + | − | − | − | − | + | − | + | − | + | + | 7594 ± 100 |
| 4 | + | − | + | + | + | + | − | − | + | + | − | + | + | − | 7280 ± 87 |
| 5 | − | − | − | − | + | − | + | − | + | + | + | + | − | − | 7782 ± 111 |
| 6 | + | + | + | + | − | − | + | + | − | + | + | − | − | − | 6652 ± 80 |
| 7 | − | − | + | − | + | − | + | + | + | + | − | − | + | + | 8849 ± 115 |
| 8 | + | + | − | − | − | − | + | − | + | − | + | + | + | + | 8033 ± 72 |
| 9 | − | + | + | − | − | − | − | + | − | + | − | + | + | + | 6088 ± 60 |
| 10 | − | + | + | + | + | − | − | + | + | − | + | + | − | − | 7656 ± 97 |
| 11 | − | + | + | − | + | + | − | − | − | − | + | − | + | − | 9602 ± 108 |
| 12 | − | + | − | + | − | + | + | + | + | − | − | + | + | − | 6903 ± 76 |
| 13 | + | + | + | − | − | + | + | − | + | + | − | − | − | − | 9037 ± 80 |
| 14 | − | − | − | + | − | + | − | + | + | + | + | − | − | + | 5962 ± 48 |
| 15 | − | − | − | − | − | − | − | − | − | − | − | − | − | − | 6150 ± 80 |
| 16 | + | − | − | − | − | + | − | + | − | + | + | + | + | − | 4958 ± 55 |
| 17 | + | − | − | + | + | − | + | + | − | − | − | − | + | − | 6401 ± 78 |
| 18 | − | − | + | + | − | + | + | − | − | − | − | + | − | + | 9163 ± 91 |
| 19 | + | + | − | − | + | + | − | + | + | − | − | − | − | + | 8661 ± 105 |
| 20 | − | + | − | + | + | + | + | − | − | + | + | − | + | + | 8033 ± 88 |
X1: NaCl; X2: (NH4)2SO4; X3: peptone; X4: peanut meal; X5: soluble starch; X6: soybean meal; X7: glucose; X8: soybean oil; X9: corn steep liquor; X10: yeast extract.
Plackett−Burman regression analysis.
| Variables | Terms | Values | Coefficient | Confidence Level (%) | |||
|---|---|---|---|---|---|---|---|
| Components (g/L) | Low (−) | High (+) | |||||
|
| NaCl | 3.5 | 5.5 | −38 | −0.13 | 0.902 | 9.8 |
|
| (NH4)2SO4 | 5.0 | 7.0 | 967 | 3.31 | 0.021 | 97.9 |
|
| Peptone | 8.0 | 10 | 1092 | 3.74 | 0.013 | 98.7 |
|
| Peanut meal | 18 | 38 | 753 | 2.58 | 0.052 | 94.8 |
|
| Soluble starch | 60 | 80 | −992 | −3.40 | 0.019 | 98.1 |
|
| Soybean meal | 4.0 | 6.0 | 351 | 1.21 | 0.282 | 71.8 |
|
| Glucose | 10 | 30 | −615 | −2.11 | 0.089 | 91.1 |
|
| Soybean oil | 2.0 | 4.0 | −163 | −0.56 | 0.600 | 40.0 |
|
| Corn steep liquor | 1.5 | 3.5 | −188 | −0.65 | 0.547 | 45.3 |
|
| Yeast extract | 5.0 | 7.0 | −452 | −1.55 | 0.182 | 81.8 |
Design of factors and levels.
| Values | |||
|---|---|---|---|
| −1 | 60 | 8 | 5 |
| 0 | 70 | 9 | 6 |
| 1 | 80 | 10 | 7 |
Response surface method (RSM) arrangements and results.
| Trial No. | NM Potency (U/mL) | |||
|---|---|---|---|---|
| 1 | −1 | −1 | 0 | 5169 ± 62 |
| 2 | 1 | 1 | 0 | 9403 ± 132 |
| 3 | 0 | −1 | −1 | 6725 ± 89 |
| 4 | −1 | 1 | 0 | 7286 ± 87 |
| 5 | 0 | 0 | 0 | 10,611 ± 153 |
| 6 | 0 | 1 | −1 | 6227 ± 75 |
| 7 | 0 | 0 | 0 | 10,608 ± 138 |
| 8 | −1 | 0 | 1 | 6040 ± 54 |
| 9 | 0 | 1 | 1 | 8780 ± 86 |
| 10 | 1 | −1 | 0 | 5667 ± 72 |
| 11 | −1 | 0 | −1 | 7784 ± 87 |
| 12 | 0 | 0 | 0 | 10,602 ± 116 |
| 13 | 1 | 0 | 1 | 8407 ± 75 |
| 14 | 0 | −1 | 1 | 6227 ± 50 |
| 15 | 1 | 0 | −1 | 10,275 ± 134 |
| 16 | 0 | 0 | 0 | 10,611 ± 118 |
| 17 | 0 | 0 | 0 | 10,608 ± 105 |
ANOVA for Box-Behnken design.
| Source | Sum of Squares | df | Mean Square | Significance | ||
|---|---|---|---|---|---|---|
| Model | 5.976 × 107 | 9 | 6.640 × 106 | 7.21 | 0.0082 | ** |
|
| 6.981 × 106 | 1 | 6.981 × 106 | 7.58 | 0.0284 | * |
|
| 7.817 × 106 | 1 | 7.817 × 106 | 8.49 | 0.0225 | * |
|
| 3.030 × 105 | 1 | 3.030 × 105 | 0.33 | 0.5842 | |
|
| 6.553 × 105 | 1 | 6.553 × 105 | 0.71 | 0.4268 | |
|
| 3844.00 | 1 | 3844.00 | 4.174 × 103 | 0.9503 | |
|
| 2.327 × 106 | 1 | 2.327 × 106 | 2.53 | 0.1559 | |
|
| 7.061 × 106 | 1 | 7.061 × 106 | 7.67 | 0.0277 | * |
|
| 2.490 × 107 | 1 | 2.490 × 107 | 27.04 | 0.0013 | ** |
|
| 5.928 × 106 | 1 | 5.928 × 106 | 6.44 | 0.0388 | * |
| Lack of Fit | 6.446 × 106 | 3 | 2.149 × 106 | 1.592 × 105 | 0.0527 | |
| Pure Error | 54.00 | 4 | 13.50 | |||
| Total | 6.621 × 107 | 16 | ||||
| 11.57 | ||||||
|
| 0.9026 | |||||
| Adjusted | 0.7774 |
* statistically significant at 95% of confidence level; ** statistically significant at 99% of confidence level.
Figure 6Response surface plots showing the effects of (X1) soluble starch, (X2) peptone, and (X3) (NH4)2SO4 on NM potency.
Figure 7The biosynthetic pathway of neomycin B. NeoC: 2-deoxy-scyllo-inosose (2DOI) synthase; NeoS: 2DOI aminotransferase; NeoE: 2-deoxy-scyllo-inosamine dehydrogenase; NeoB: 6′-oxoparomamine aminotransferase; NeoN: neomycin C 5‴-epimerase.